exv10w2






Exhibit 10.2




Execution Copy




 





NOVATED AND RESTATED




TECHNOLOGY LICENSE AGREEMENT




among




OXiGENE, INC.,




SYMPHONY ViDA, INC.




and




SYMPHONY ViDA HOLDINGS LLC




 






Dated as of October 1, 2008




 





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.






 









 







Confidential Treatment Requested





 









 








TABLE OF CONTENTS




	 	 	 	 	 
	 	 	Page	 
	ARTICLE 1 DEFINITIONS
	 	 	1	 
	 
	 	 	 	 
	ARTICLE 2 GRANT OF RIGHTS
	 	 	1	 
	 
	 	 	 	 
	2.1 Assignment
	 	 	1	 
	2.2 License Grant
	 	 	2	 
	2.3 Sublicense to Licensor
	 	 	2	 
	2.4 Right to Sublicense
	 	 	2	 
	2.5 Partial Reversion of License upon Licensor’s Exercise of
Discontinuation Option
	 	 	3	 
	2.6 IV Ophthalmology Limitation, Reservation of Rights & Restrictive
Covenant
	 	 	4	 
	2.7 Regulatory Files After Expiration or Termination of Term or
Discontinuation Option
	 	 	6	 
	2.8 Delivery of Materials After Expiration or Termination of Term
	 	 	7	 
	2.9 License Opportunities
	 	 	8	 
	2.10 Separate Third Party License for Discontinued Program
	 	 	9	 
	2.11 Supply of Product After Expiration or Termination of Term
	 	 	9	 
	2.12 Post-Term Zybrestat Cross-Licenses
	 	 	9	 
	 
	 	 	 	 
	ARTICLE 3 SUBLICENSE TO CERTAIN THIRD PARTY INTELLECTUAL PROPERTY
	 	 	10	 
	 
	 	 	 	 
	3.1 Third Party Sublicense Payments
	 	 	10	 
	3.2 Sublicensed Intellectual Property
	 	 	10	 
	 
	 	 	 	 
	ARTICLE 4 INTELLECTUAL PROPERTY
	 	 	11	 
	 
	 	 	 	 
	4.1 Ownership
	 	 	11	 
	4.2 Marking
	 	 	11	 
	4.3 Prosecution and Maintenance
	 	 	11	 
	4.4 Abandonment
	 	 	13	 
	4.5 Infringement
	 	 	13	 
	4.6 Enforcement Right During Term
	 	 	13	 
	4.7 Post-Term Enforcement
	 	 	15	 
	4.8 Withdrawal of Enforcement
	 	 	17	 





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.




-i-









 





TABLE OF CONTENTS

(continued)




	 	 	 	 	 
	 	 	Page	 
	4.9 Recoveries
	 	 	17	 
	 
	 	 	 	 
	ARTICLE 5 REPRESENTATIONS AND WARRANTIES
	 	 	17	 
	 
	 	 	 	 
	5.1 Representations and Warranties of Licensor
	 	 	17	 
	5.2 Disclaimer and Acknowledgement
	 	 	19	 
	 
	 	 	 	 
	ARTICLE 6 INDEMNIFICATION AND LIMITATION OF LIABILITY
	 	 	19	 
	 
	 	 	 	 
	6.1 Indemnification
	 	 	19	 
	6.2 Notice of Claims
	 	 	21	 
	6.3 Defense of Proceedings
	 	 	21	 
	6.4 Settlement
	 	 	23	 
	6.5 Limitation of Liability
	 	 	23	 
	6.6 Insurance
	 	 	23	 
	 
	 	 	 	 
	ARTICLE 7 TERM AND TERMINATION
	 	 	24	 
	 
	 	 	 	 
	7.1 Term
	 	 	24	 
	7.2 Termination
	 	 	24	 
	7.3 Survival
	 	 	24	 
	7.4 Bankruptcy
	 	 	24	 
	 
	 	 	 	 
	ARTICLE 8 MISCELLANEOUS
	 	 	25	 
	 
	 	 	 	 
	8.1 Notices
	 	 	25	 
	8.2 Entire Agreement
	 	 	26	 
	8.3 Assignment
	 	 	26	 
	8.4 Headings
	 	 	26	 
	8.5 Independent Contractor
	 	 	27	 
	8.6 Severability
	 	 	27	 
	8.7 No Third-Party Beneficiaries
	 	 	27	 
	8.8 Compliance with Laws
	 	 	27	 
	8.9 Amendment
	 	 	27	 
	8.10 Governing Law; Consent to Jurisdiction and Service of Process
	 	 	27	 
	8.11 Waiver of Jury Trial
	 	 	28	 
	8.12 Counterparts
	 	 	28	 





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





-ii-









 





TABLE OF CONTENTS

(continued)




	 	 	 	 	 
	 	 	Page	 
	8.13 No Waiver
	 	 	28	 





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





-iii-









 






TABLE OF CONTENTS

(continued)




	 	 	 	 	 
	 	 	 	 	Page
	ANNEX A

	 	CERTAIN DEFINITIONS
	 	 
	 
	 	 	 	 
	ANNEX B

	 	CERTAIN ROYALTY AND MILESTONE PAYMENTS	 	 
	 
	 	 	 	 
	ANNEX C

	 	CERTAIN LICENSED PATENTS	 	 
	 
	 	 	 	 
	SCHEDULE 2.2

	 	CERTAIN RESTRICTIONS RELATING TO LICENSED INTELLECTUAL PROPERTY LICENSED TO

LICENSOR BY A THIRD PARTY	 	 
	 
	 	 	 	 
	SCHEDULE 5.1

	 	OXIGENE COLLABORATION TECHNOLOGY THAT RELATES TO OR IS EXPLOITABLE IN

CONNECTION WITH LICENSED INTELLECTUAL PROPERTY, REGULATOR FILES, PRODUCTS

AND/PROGRAMS	 	 





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.






-iv-









 








NOVATED AND RESTATED

TECHNOLOGY LICENSE AGREEMENT




          This NOVATED AND RESTATED TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) is made and
effective as of October 1, 2008 by and among OXiGENE, Inc., a Delaware corporation (the
“Licensor”), Symphony ViDA, Inc., a Delaware corporation (the “Symphony
Collaboration”) (each of Licensor and the Symphony Collaboration being a “Party,” and
collectively, the “Parties”), and Symphony ViDA Holdings LLC, a Delaware limited liability
company (“Holdings”).




          WHEREAS, Licensor and Holdings have entered into that certain Technology License Agreement,
dated October 1, 2008 (the “Original Agreement”);




          WHEREAS, Holdings desires to assign its right, title and interest in, and delegate and novate
its obligations under the Original Agreement to the Symphony Collaboration, and Licensor and the
Symphony Collaboration desire to novate and restate the terms and conditions of the Original
Agreement to effect such novation;




          WHEREAS, Licensor owns or has rights in certain technology, know-how, patents and other
intellectual property rights related to the design, development, manufacture and/or use of the
Products;




          WHEREAS, Licensor desires to grant to the Symphony Collaboration, and the Symphony
Collaboration desires to acquire, the exclusive right to use such technology, know-how, patents and
other intellectual property rights to develop and commercialize Products on the terms and
conditions of this Agreement; and




          WHEREAS, Licensor desires to receive, and the Symphony Collaboration desires to grant to
Licensor, the exclusive right to use such technology, know-how, patents and other intellectual
property rights to develop Products on behalf of the Symphony Collaboration on the terms and
conditions of this Agreement.




          NOW THEREFORE, in consideration of the mutual promises and agreements set forth herein, and
for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties agree as follows:




ARTICLE 1

DEFINITIONS




          Capitalized terms used herein and not defined shall have the meanings assigned to such terms
in Annex A attached hereto.




ARTICLE 2

GRANT OF RIGHTS




          2.1 Assignment. Holdings hereby assigns to the Symphony Collaboration all of its
right, title and interest in and to the Original Agreement. The



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.






 









 







Parties agree that from and after the Closing Date, all of the right, title, interest and
obligations of Holdings under the Original Agreement will be assigned, novated and transferred to,
and assumed by, the Symphony Collaboration, as amended and restated by this Agreement.




          2.2 License Grant. Subject to Sections 2.3, 2.4, 2.5, and 2.6 below, the
limitations and restrictions set forth on Schedule 2.2, and the terms and conditions of
this Agreement, Licensor, on behalf of itself and its Affiliates, hereby grants to the Symphony
Collaboration a fully paid, worldwide, exclusive license under the Licensed Intellectual Property,
solely to make, have made, develop, use, offer for sale, sell, and import Products. For the
avoidance of doubt, the license grant extends only to the field of the Products and/or the
Programs. Licensor is free, without seeking or obtaining consent of the Symphony Collaboration, to
license the Licensed Intellectual Property for exploitation outside the fields of the Product
and/or the Programs, including, but not limited to, use of any Zybrestat Compound in any cancer
treatment or therapy, other than malignant neoplastic tumors of the eye treated by via non-systemic
administration of a Vascular Disrupting Agent.




          2.3 Sublicense to Licensor. The Symphony Collaboration hereby grants to Licensor a
fully paid, worldwide, exclusive (even as to the Symphony Collaboration) sublicense under the
Licensed Intellectual Property, with the right to grant further sublicense(s), solely to the extent
required for Licensor to perform its obligations or exercise its rights under the Operative
Documents. Notwithstanding the foregoing, Licensor shall only exercise its rights as sublicensee
hereunder in connection with and for the purpose of carrying out Licensor’s obligations or
exercising Licensor’s rights under the Operative Documents. In the event of the expiration of a
Discontinuation Option without exercise by Licensor, the sublicense set forth in this Section
2.3 shall expire with respect to the Products relating to the Program to which such
Discontinuation Option pertained. Upon the unexercised expiration or termination of the Purchase
Option without Licensor’s exercise of the Purchase Option, the sublicense set forth in this
Section 2.3 shall expire with respect to all Products relating to the Program(s) for which
Licensor has not exercised the Discontinuation Option.




          2.4 Right to Sublicense. Subject to the limitations and restrictions set forth on
Schedule 2.2, the license granted hereunder includes the right of the Symphony
Collaboration to grant sublicenses under the Licensed Intellectual Property, provided, that,




               (a) subject to Sections 2.3 and 2.4(b), the Symphony Collaboration shall not
sublicense any of the rights granted pursuant to Section 2.2 to any third party (including
without limitation any Affiliates) prior to the expiration or termination of the Purchase Option
without Licensor’s exercise of the Purchase Option;



               (b) notwithstanding (a), in the event of the expiration of a Discontinuation Option without
exercise by Licensor, the Symphony Collaboration may


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





2









 







grant to third parties (including without limitation Affiliates) sublicenses of the rights
granted pursuant to Section 2.2 with respect to the Products relating to the Program to
which such Discontinuation Option pertained;




               (c) each sublicense granted (i) is pursuant to a written contract, (ii) is consistent with the
terms of this Agreement, (iii) does not grant any rights beyond the scope of the license rights
granted herein, and (iv) is as protective of Licensor’s rights as set forth in this Agreement; and



               (d) the Symphony Collaboration shall notify Licensor of the execution of any sublicense
agreement, identifying the sublicensee and the scope of the sublicense, and upon Licensor’s written
request, the Symphony Collaboration shall provide to Licensor copies of any sublicense agreements,
provided that (i) the Symphony Collaboration may redact any financial or other proprietary
information contained therein which does not affect Licensor’s rights and (ii) Licensor shall treat
its copy of the sublicense agreements as Confidential Information of the Symphony Collaboration.



          2.5 Partial Reversion of License upon Licensor’s Exercise of Discontinuation Option.




               (a) Licensor and the Symphony Collaboration acknowledge that Licensor may exercise its
Discontinuation Option pursuant to Section 11 of the Amended and Restated Research and Development
Agreement. Upon the Discontinuation Option Closing Date, as applicable, (i) the license set forth
in Section 2.2 (and the corresponding sublicense under Section 2.3) shall expire
with respect to the Products relating to the Program for which Licensor exercised its
Discontinuation Option, as applicable, (ii) those patents, patent applications, Know-How and the
Symphony Collaboration Enhancements that were part of the Licensed Intellectual Property as of the
applicable Discontinuation Option Closing Date and relate exclusively to such Program (including
its Products) but not to any other Program, shall be deleted from the relevant intellectual
property definitions, and accordingly, the Symphony Collaboration shall no longer be responsible
for any obligations or costs (including royalties or fees to third parties, prosecution costs,
maintenance costs and enforcement costs) accruing after such Discontinuation Option Closing Date
with respect to such patents, patent applications, Know-How and the Symphony Collaboration
Enhancements; and (iii) the Symphony Collaboration shall (a) at Licensor’s request and option,
promptly return to Licensor or destroy all Tangible Materials relating solely to such Program; and
(b) upon Licensor’s request, provide Licensor a copy of all Tangible Materials which relate to such
Program (but not solely to such Program). The Parties shall, as necessary, promptly amend this
Agreement, in connection with the exercise and consummation of the Discontinuation Option pursuant
to Section 11 of the Amended and Restated Research and Development Agreement, and at Licensor’s
request, the Symphony Collaboration shall perform such acts and execute such documents as Licensor
may reasonably deem necessary or desirable, to give Licensor all rights it needs to pursue the
Program for which such


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





3









 







Discontinuation Option was exercised without any obligation to or dependency on the Symphony
Collaboration and to limit this Agreement to the other Program.




               (b) Upon the Discontinuation Option Closing Date, Licensor and the Symphony Collaboration
shall take all actions necessary to effect the assignment to the Licensor of the sponsorship to the
Regulatory Files, if any, owned or Controlled by the Symphony Collaboration with respect to the
Program for which the Discontinuation Option was exercised. After any such Regulatory Files are
assigned to Licensor, the Symphony Collaboration shall have no further rights therein or
obligations thereunder; provided, however, that during the [ * ] days following such assignment of
Regulatory Files, at Licensor’s reasonable request and expense, the Symphony Collaboration shall
use commercially reasonable efforts to provide the Licensor with assistance in respect of such
Regulatory Files. The Symphony Collaboration shall, at the reasonable request of Licensor and at
Licensor’s expense, perform any acts that the Licensor may reasonably deem necessary or desirable
to evidence or confirm the Licensor’s ownership interest in such Regulatory Files, including, but
not limited to, making further written assignments in a form reasonably determined by Licensor.



          2.6 IV Ophthalmology Limitation, Reservation of Rights & Restrictive Covenant.




               (a) IV Ophthalmology Limitation.




               (i) The Symphony Collaboration shall not conduct any IV Commercialization Activities
without the consent of Licensor, provided that if the Symphony Collaboration requests such
consent in accordance with Section 2.6(a)(iii), such consent may only be withheld
in the event that Licensor believes in good faith that the licensing and/or
commercialization of any Zybrestat Compound for use in any cancer treatment or therapy will
be benefited by prohibiting the Symphony Collaboration from conducting IV Commercialization
Activities.




               (ii) The Symphony Collaboration shall, as soon as practicable, determine in good faith
if it believes that the development of an IV Ophthalmology Product is commercially viable,
and shall inform Licensor of its conclusion. If the conclusion is that the development of
an IV Ophthalmology Product is not commercially viable, the Symphony Collaboration shall
thereafter be prohibited from conducting any IV Commercialization Activities without regard
to the balance of this Section 2.6(a).




               (iii) The Symphony Collaboration may only request consent as set forth in Section
2.6(a)(i), if (A) the Symphony Collaboration has determined that the development of an
IV Ophthalmology Product is commercially viable, (B) the Symphony Collaboration plans in
good faith to conduct IV Commercialization Activities after receiving such consent, and
(C) the


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





4









 









Symphony Collaboration will start to incur, within a commercially reasonable period of
time following any such consent, material expense in initiating any clinical study, in
accordance with the then-current and approved Development Plan, which is either (1) a
pivotal registration study; or (2) provided the Non-Pivotal Requirements are met, any other
clinical study related to an IV Ophthalmology Product.




               (iv) In addition, in the event that Licensor believes in good faith that the licensing
and/or commercialization of any Zybrestat Compound for use in any oncology indication will
be benefited by prohibiting the Symphony Collaboration from conducting IV Commercialization
Activities, Licensor shall have the right to issue to the Symphony Collaboration a Non-IV
Notice.




               (v) In the event Licensor issues a Non-IV Notice or denies a request for consent from
the Symphony Collaboration made in accordance with Section 2.6(a)(iii) to conduct
any IV Commercialization Activities, then Section 2.06 of the Stock and Warrant Purchase
Agreement shall apply.



               (b) Reservation of Rights. All rights not expressly granted to a Party hereunder
shall remain the exclusive property of the other Party. The Symphony Collaboration covenants and
agrees that it will not, and will cause its Affiliates not to use or exploit the Licensed
Intellectual Property outside of the scope of the licenses granted herein. For clarity, the
Symphony Collaboration and its Affiliates shall not use or exploit the Licensed Intellectual
Property for any purpose other than the development, manufacture, use, sale or importation of
Products. Licensor covenants and agrees that Licensor will not, and will cause its Affiliates not
to, use or exploit the Licensed Intellectual Property in connection with the development,
manufacture, use, sale, or importation of Products after the expiration of all sublicenses granted
pursuant to Section 2.3; provided, however, that such covenant by Licensor shall not apply
to any Program for which Licensor exercises a Discontinuation Option or to any Products relating to
such Program. For the avoidance of doubt, except as set forth below in Section 2.6(c),
Licensor and its Affiliates shall not be restricted from using or otherwise exploiting the Licensed
Intellectual Property with respect to products that are not Products and/or programs that are not
Programs.



               (c) Restrictive Covenant. Except in connection with Licensor’s performance of its
obligations pursuant to the Operative Documents, Licensor shall not, and shall cause its Affiliates
not to, independently or in conjunction with a third party (via license or otherwise) perform
research related to, develop (including, but not limited to, preclinical and clinical development),
or otherwise participate in activities related to the development or commercialization of,
Ophthalmology Products or Second Generation OQP Products; provided, however, that such covenant by
Licensor shall not apply to any Program for which Licensor exercises a Discontinuation Option or to
any


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.






5









 







Products relating to such Program. For the avoidance of doubt, this Section 2.6(c)
shall survive the unexercised expiration or termination of the Purchase Option without Licensor’s
exercise of the Purchase Option.




          2.7 Regulatory Files After Expiration or Termination of Term or Discontinuation
Option.




               (a) As soon as reasonably practical after the expiration or termination of the Purchase Option
without exercise by Licensor and as of a date to be agreed upon by Licensor and the Symphony
Collaboration, Licensor and the Symphony Collaboration shall, at the Symphony Collaboration’s
expense, take all actions necessary to effect the assignment to the Symphony Collaboration or its
designee of the sponsorship to the Regulatory Files with respect to the Programs for which Licensor
has not exercised its Discontinuation Option. After such Regulatory Files are assigned to the
Symphony Collaboration, Licensor shall have no further rights therein or obligations thereunder;
provided, however, that during the [ * ] days following such assignment of Regulatory Files, at the
Symphony Collaboration’s reasonable request and expense, Licensor shall use commercially reasonable
efforts to provide the Symphony Collaboration or its designee with assistance in respect of such
Regulatory Files. Licensor shall, at the reasonable request of the Symphony Collaboration and at
the Symphony Collaboration’s expense, perform any acts that the Symphony Collaboration may
reasonably deem necessary or desirable to evidence or confirm the Symphony Collaboration’s
ownership interest in such Regulatory Files, including, but not limited to, making further written
assignments in a form reasonably determined by the Symphony Collaboration. Without limiting the
license rights granted under this ARTICLE 2, the Parties understand and agree that the assignment
of such Regulatory Files does not include an assignment of any Licensed Intellectual Property.



               (b) As soon as reasonably practical after the expiration of a Discontinuation Option without
exercise by Licensor and as of a date to be agreed upon by Licensor and the Symphony Collaboration,
Licensor and the Symphony Collaboration shall, at the Symphony Collaboration’s expense, take all
actions necessary to effect the assignment to the Symphony Collaboration or its designee of the
sponsorship to the Regulatory Files with respect to the Program for which the Discontinuation
Option has so expired. After such Regulatory Files are assigned to the Symphony Collaboration,
Licensor shall have no further rights therein or obligations thereunder; provided, however, that
during the [ * ] days following such assignment of Regulatory Files, at the Symphony
Collaboration’s reasonable request and expense, Licensor shall use commercially reasonable efforts
to provide the Symphony Collaboration or its designee with assistance in respect of such Regulatory
Files. Licensor shall, at the reasonable request of the Symphony Collaboration and at the Symphony
Collaboration’s expense, perform any acts that the Symphony Collaboration may reasonably deem
necessary or desirable to evidence or confirm the Symphony Collaboration’s ownership interest in
such Regulatory Files, including, but not limited to, making further written assignments in a form
reasonably determined by the Symphony Collaboration. Without limiting the


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.






6









 







license rights granted under this ARTICLE 2, the Parties understand and agree that the
assignment of such Regulatory Files does not include an assignment of any Licensed Intellectual
Property.




               (c) Right To Reference Symphony Regulatory Files. Effective upon the expiration or
termination of the Purchase Option without Licensor’s exercise of the Purchase Option, or the
expiration of the Discontinuation Option for the Ophthalmology Program without exercise by
Licensor, the Symphony Collaboration hereby grants to Licensor a fully paid, worldwide,
non-exclusive license, with the right to grant sublicenses, to reference and otherwise have access
to the Symphony Regulatory Files (including any DMF therein) solely in connection with the
development and commercialization of Zybrestat Compounds for use in connection with cancer
treatment or therapy (other than the treatment of neoplastic tumors of the eye treated via methods
other than systemic administration of a Vascular Disrupting Agent).



               (d) Right To Reference Licensor Regulatory Files. Effective upon the expiration or
termination of the Purchase Option without Licensor’s exercise of the Purchase Option, Licensor, on
behalf of itself and its Affiliates, hereby grants to the Symphony Collaboration a fully paid,
worldwide, non-exclusive license, with the right to grant sublicenses, to reference and otherwise
have access to the Licensor Regulatory Files, solely in connection with the development and
commercialization of Ophthalmology Products. For the avoidance of doubt, this Section
2.7(d) shall not in any way limit the Symphony Collaboration’s rights pursuant to Sections
2.7(a) or 2.7(b).



          2.8 Delivery of Materials After Expiration or Termination of Term.




               (a) Upon the expiration or termination of the Purchase Option without exercise by Licensor,
Licensor shall, at the Symphony Collaboration’s expense, promptly deliver to the Symphony
Collaboration all copies of Tangible Materials existing as of the date of such unexercised
expiration or termination that relate to the Programs for which Licensor has not exercised its
Discontinuation Option; provided, however, that Licensor may also retain copies of (and the right
to use) those Tangible Materials that are required to be delivered to the Symphony Collaboration
hereunder but which also relate to (i) any Program for which Licensor has exercised its
Discontinuation Option or (ii) any other program or product of Licensor, including without
limitation, the development and commercialization of Zybrestat Compounds for use in connection with
cancer treatment or therapy (other than the treatment of neoplastic tumors of the eye treated via
methods other than systemic administration of a Vascular Disrupting Agent).



               (b) In the event of the expiration of a Discontinuation Option without exercise by Licensor,
Licensor shall, at the Symphony Collaboration’s expense, promptly deliver to the Symphony
Collaboration all copies of Tangible Materials existing as of the date of such expiration that
relate to the Program to which the Discontinuation Option pertained; provided, however, that
Licensor may also retain copies of (and the right to use) those Tangible Materials that are
required to be delivered to the Symphony


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





7









 







Collaboration hereunder but which also relate to (i) any other Program or (ii) any other
program or product of Licensor, including without limitation, the development and commercialization
of Zybrestat Compounds for use in connection with cancer treatment or therapy (other than the
treatment of neoplastic tumors of the eye treated via methods other than systemic administration of
a Vascular Disrupting Agent).




          2.9 License Opportunities. In the event that, during the Term, Licensor reasonably
determines that it is necessary to license from any third party any intellectual property relating
to the composition of matter, use, manufacture, formulation or exploitation of the Products
(“Third Party IP”) and Licensor desires to license such Third Party IP during the Term,
then (i) if Licensor desires the Symphony Collaboration to pay any or all of the financial
obligations under such license, Licensor shall obtain the Symphony Collaboration’s written consent,
which shall not be unreasonably withheld or delayed, before acquiring such license; and (ii) if the
Symphony Collaboration provides such consent, then unless otherwise agreed to by the Parties in
writing, Licensor shall use commercially reasonable efforts to obtain, at the time such license is
granted, the right to sublicense such Third Party IP to the Symphony Collaboration consistent with
the terms of this Agreement as if such Third Party IP were Licensed Intellectual Property. Unless
otherwise agreed to by the Parties in writing, the financial obligations under any license to Third
Party IP obtained by Licensor with the Symphony Collaboration’s consent shall (1) be borne fully by
the Symphony Collaboration if (A) such Third Party IP relates solely to the composition of matter,
use, manufacture, formulation or exploitation of the Products or (B) such license is limited in
scope to the composition of matter, use, manufacture, formulation or exploitation of one or more
Products, and, at the time of entering into such third party license, Licensor has not exercised
its Discontinuation Option with respect to the Program to which such Third Party IP or scope of
such license relates; or (2) be shared by the Parties in amounts and/or percentages to be agreed
upon by the Parties prior to Licensor entering into such third party license, if such Third Party
IP or scope of such license relates (but does not relate solely) to the composition of matter, use,
manufacture, formulation or exploitation of Products within Program(s) for which Licensor has not
exercised its Discontinuation Option and also relates to either (x) the composition of matter, use,
manufacture, formulation or exploitation of Products within Program(s) for which Licensor has
exercised its Discontinuation Option or (y) the composition of matter, use, manufacture,
formulation or exploitation of other products of Licensor; or (3) be borne fully by Licensor if
such Third Party IP or scope of such license relates solely to the composition of matter, use,
manufacture, formulation or exploitation of Product(s) within a Program(s) for which Licensor has
exercised its Discontinuation Option. Notwithstanding the foregoing, Licensor shall have no
obligation to obtain any such third party licenses under this Agreement or, in the event that the
Symphony Collaboration does not give such consent, to grant any sublicenses to the Symphony
Collaboration. Upon obtaining a license to such Third Party IP and the right to sublicense to the
Symphony Collaboration, the Parties will, as necessary, promptly amend this Agreement to include
such sublicensed intellectual property within the license granted hereunder, incorporate any other
limitations, royalties or other provisions required by such third party with respect to such
sublicense, and address the Symphony



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





8









 







Collaboration’s rights (if any) with respect to patent prosecution, maintenance and
enforcement of patents and patent applications within such Third Party IP.




          2.10 Separate Third Party License for Discontinued Program. In the event of the
expiration of a Discontinuation Option without exercise by Licensor, the Symphony Collaboration has
the right to transfer to a third party the Symphony Collaboration’s rights to the Products relating
to the Program to which such Discontinuation Option pertained (the “Discontinued Program”).
If the Symphony Collaboration identifies a third party that wishes to obtain such rights, then
upon the Symphony Collaboration’s request, (i) Licensor and the Symphony Collaboration shall amend
this Agreement to terminate all of the Symphony Collaboration’s rights and obligations to the
extent applicable to the Discontinued Program and (ii) Licensor shall enter into a separate license
agreement with such third party in which all of such terminated rights and obligations shall be
conferred upon and undertaken by such third party. The terms and conditions of such license
agreement shall be identical to those contained herein, to the extent that such terms are
applicable to the Discontinued Program and not dependent on any Operative Document other than this
Agreement. Such terms shall include but not be limited to (1) provisions allowing for termination
of such license agreement upon a material, uncured breach of such license agreement by the third
party on similar terms as provided herein with respect to the Symphony Collaboration and (2) a
confidentiality provision that is not dependent on any of the Operative Documents. Termination of
this Agreement shall not effect such license agreement and Licensor’s obligation to enter into such
a license agreement shall survive termination of this Agreement.




          2.11 Supply of Product After Expiration or Termination of Term. In the event of
expiration or termination of the Purchase Option without exercise by Licensor, without limiting
Licensor’s other obligations pursuant to the Operative Documents, during the [ * ] day period
following any such expiration or termination, Licensor agrees to cooperate in good faith and
provide reasonable assistance to the Symphony Collaboration (or its partners or transferees
hereunder), at the expense of the Symphony Collaboration, in connection with the transition of the
continued development (including, but not limited to, clinical development), manufacture and
commercialization of Products by the Symphony Collaboration (or its partners or transferees
hereunder), including, but not limited to, the supply of active ingredients or other compositions
of matter during such period.




          2.12 Post-Term Zybrestat Cross-Licenses.




               (a) Symphony Collaboration License Grant. Effective upon the expiration or
termination of the Purchase Option without Licensor’s exercise of the Purchase Option, the Symphony
Collaboration hereby grants to Licensor a fully paid, worldwide, non-exclusive license, with the
right to grant sublicenses, under the Symphony Zybrestat Patents, solely to make, have made,
develop, use, offer for sale, sell,


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





9









 







and import Zybrestat Compounds solely for use other than the non-systemic administration of
Zybrestat for treatment of, or therapies related to, diseases of the eye.




               (b) Licensor License Grant. Effective upon the expiration or termination of the
Purchase Option without Licensor’s exercise of the Purchase Option, Licensor, on behalf of itself
and its Affiliates, hereby grants to the Symphony Collaboration a fully paid, worldwide,
non-exclusive license, with the right to grant sublicenses, under the Licensor Zybrestat Patents,
solely to make, have made, develop, use, offer for sale, sell, and import Ophthalmology Products.
For the avoidance of doubt, the license granted pursuant to this Section 2.12(b) shall not
in any way limit the license granted pursuant to Section 2.2.



ARTICLE 3

SUBLICENSE TO CERTAIN THIRD PARTY INTELLECTUAL PROPERTY




          3.1 Third Party Sublicense Payments. Unless otherwise agreed to by the Parties in
writing, to the extent that (a) any Licensed Intellectual Property is licensed to Licensor pursuant
to a Third Party License Agreement and the development, manufacture, use, sale or other
commercialization of any Product by the Symphony Collaboration shall require the Licensor to make a
royalty payment, milestone or any other payment obligation to the third party licensor of such
Licensed Intellectual Property, (i) the Symphony Collaboration shall be responsible for the
satisfaction of such royalty payment, milestone or any other obligation to such licensor if such
payment is triggered by the development, manufacture, use, sale or other commercialization of any
Product by the Symphony Collaboration (including, without limitation, by Licensor in the
performance of the Amended and Restated Research and Development Agreement); or (ii) such royalty
payment shall be shared by the Parties in amounts and/or percentages to be agreed upon by the
Parties if such payment relates (but does not relate solely) to the manufacture, use, sale or other
commercialization of any Product by the Symphony Collaboration (including, without limitation, by
Licensor in the performance of the Amended and Restated Research and Development Agreement).
Notwithstanding the foregoing, with respect to Third Party License Agreements existing as of the
Closing Date, the Symphony Collaboration’s obligations under this Section 3.1 for Products
will be limited solely to those royalties and milestones set forth on Annex B.




          3.2 Sublicensed Intellectual Property. The Symphony Collaboration acknowledges
(i) that certain Licensed Intellectual Property is licensed to Licensor or its Affiliates pursuant
to the Third Party License Agreements and will be sublicensed to the Symphony Collaboration
hereunder (the “Sublicensed Intellectual Property”) and (ii) that such sublicense is
subject to certain restrictions and obligations set forth in the applicable Third Party License
Agreements (the “Sublicense Obligations”), including but not limited to those restrictions
and obligations set forth on Schedule 2.2. The Symphony Collaboration agrees to either be
bound by the Sublicense Obligations or forfeit the applicable sublicense of such Intellectual
Property under Section 2.2; provided, however, that the Symphony Collaboration cannot use
this Section 3.2 to avoid any Sublicense



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





10









 







Obligation that has accrued after the Closing Date and prior to the date the Symphony
Collaboration elects to forfeit the applicable sublicense. Licensor shall not, without the prior
written consent of the Symphony Collaboration (which such consent shall not be unreasonably
withheld or delayed), fail to timely and diligently pursue and exercise any option or right,
pursuant to any agreement between Licensor or its Affiliates and a third party, to obtain rights
for the Symphony Collaboration in any patent, patent application, invention disclosure or Know-How
that relates to, or is exploitable in connection with, any Licensed Intellectual Property,
Regulatory Files, Products and/or Programs, and all such rights obtained shall be considered
Sublicensed Intellectual Property hereunder. Licensor shall provide the Symphony Collaboration
with prompt written notice of the termination or purported termination of any Third Party License
Agreement.




ARTICLE 4

INTELLECTUAL PROPERTY




          4.1 Ownership. The Parties acknowledge and agree that, as between Licensor and the
Symphony Collaboration, and subject to Schedule 2.2, Licensor or its licensors are the
owners of all right, title and interest in and to the Licensed Intellectual Property, including
without limitation the Symphony Collaboration Enhancements and the Regulatory Files. The Symphony
Collaboration hereby assigns to Licensor all of the Symphony Collaboration’s rights and interests
in any Symphony Collaboration Enhancement, including any rights in inventions made jointly by
Licensor and the Symphony Collaboration. The Symphony Collaboration shall promptly disclose any
Symphony Collaboration Enhancement to Licensor, and shall use reasonable efforts, at Licensor’s
request and at no cost to Licensor, to cooperate fully with Licensor to transfer such Symphony
Collaboration Enhancements to Licensor. For the avoidance of doubt, Licensor shall have no
interest in or rights, other than that provided by Section 2.12, in connection with any
Know-How (including findings, improvements, discoveries, inventions, additions, modifications,
enhancements, derivative works, clinical development data, or changes to the Licensed Know-How,
Regulatory Files, Products or the Programs), that is made by or on behalf of the Symphony
Collaboration subsequent to the expiration or termination of the Purchase Option without Licensor’s
exercise of the Purchase Option.




          4.2 Marking. The Symphony Collaboration shall mark, and shall cause all of its
sublicensees to mark, all Products, or the packaging thereof or materials related thereto, with the
number of the applicable patents licensed hereunder in accordance with the applicable
jurisdiction’s patent law.




          4.3 Prosecution and Maintenance.




               (a) Unless otherwise set forth in this Section 4.3, (i) Licensor shall prepare, file,
prosecute and maintain all patents and patent applications in Licensed Patent Rights for which
Licensor has patent prosecution and maintenance rights (including without limitation all such
patents and patent applications in the Sublicensed


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





11









 







Intellectual Property); and (ii) Licensor shall provide the Symphony Collaboration with
(1) quarterly reports regarding the status of the prosecution and maintenance of Licensed Patent
Rights, (2) copies of and/or access to any patent documents related to the Licensed Patent Rights
as reasonably requested by the Symphony Collaboration, (3) copies of patent applications and other
substantive patent prosecution documents pertaining to the Program-Specific Patents prior to filing
in the United States so as to afford the Symphony Collaboration and its patent counsel, at the
Symphony Collaboration’s expense, a reasonable opportunity to review and comment on such documents
and (4) timely answers to the Symphony Collaboration’s questions regarding the status of patents
and patent applications in Licensed Patent Rights.




               (b) Licensor will use commercially reasonable efforts to seek the allowance of broad generic
claims that read on Products as well as Program-Specific Claims, consistent with Licensor’s
determination of enforceability, business considerations and other factors.



               (c) Subject to a reasonable allocation of costs in the event that any Program-Specific Patent
relates to Licensor’s business other than the Programs, the cost of the prosecution and maintenance
of Program-Specific Patents shall be paid by the Symphony Collaboration. Upon the scope of any
Licensed Patent Rights being amended so that the patent or patent application’s claims no longer
relate to, or are exploitable in connection with, any Product and/or any Program, for which
Licensor has not exercised a Discontinuation Option, such patent or patent application shall cease
to be a Licensed Patent Right and all rights and obligations with respect to such patent or patent
application (including costs, fees, prosecution, maintenance and enforcement) shall revert to
Licensor.



               (d) The Symphony Collaboration shall not be responsible for the costs of any interference or
reexamination initiated by Licensor with respect to the Program-Specific Patents (except to the
extent allocated in the Development Budget), unless the Parties mutually agree in writing (i) that
it is reasonably necessary or useful to file and prosecute such interference or re-examination in
connection with such Program-Specific Patents to protect their interests in such Program-Specific
Patents and (ii) to a reasonable allocation of costs in the event that any Program-Specific Patents
relate to Licensor’s business other than the Programs, which agreement will not be unreasonably
withheld or delayed. In the event, however, that (i) the Symphony Collaboration does not agree to
pay such costs (or its share of costs as reasonably allocated as set forth above) of such
interference or reexamination and (ii) Licensor successfully files and prosecutes or settles such
interference or reexamination at its sole cost, then the licenses granted by Licensor to the
Symphony Collaboration in Section 2.2 herein shall immediately terminate with respect to
specific Program-Specific Patent subject to such interference or reexamination.



               (e) The Symphony Collaboration shall not be responsible for the costs of any opposition,
protest or reexamination initiated by Licensor with respect to


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





12









 







any intellectual property rights owned or controlled by a third party, including those related
to any pending patent application, (except to the extent allocated in the Development Budget),
unless the Parties mutually agree in writing (i) that it is reasonably necessary or useful to file
and prosecute such opposition, protest or reexamination in connection with such third party
intellectual property to protect their interests in the Programs and (ii) to a reasonable
allocation of costs in the event that such third party intellectual property relates to Licensor’s
business other than the Programs, which agreement will not be unreasonably withheld or delayed.




               (f) Each Party shall provide the prosecuting Party with reasonable cooperation under this
Section 4.3.



          4.4 Abandonment. Subject to the limitations and restrictions set forth on
Schedule 2.2, Licensor shall not cancel a Program-Specific Claim or abandon a
Program-Specific Patent without [ * ]. If the Symphony Collaboration does not provide such consent
[ * ] upon Licensor’s request, then Licensor may (i) continue to prosecute such Program-Specific
Claim in the patent application in which it is currently pending, or (ii) cancel such
Program-Specific Claim in a manner that allows future prosecution of such claim and then propose
such claim in a newly filed divisional or continuation application that the Symphony Collaboration
may prosecute at its expense (including reimbursing Licensor for the costs associated with filing
such divisional or continuation application) in the name of Licensor and in the Symphony
Collaboration’s discretion.




          4.5 Infringement. Each Party agrees to immediately notify the other Party upon
becoming aware of any infringement, misappropriation, illegal use or misuse of the Licensed
Intellectual Property in connection with Products and provide to the other Party all available
evidence of such infringement.




          4.6 Enforcement Right During Term.




               (a) Except as provided in Section 4.6(b), prior to the expiration or termination of
the Purchase Option without Licensor’s exercise of the Purchase Option, Licensor has the first
right, but not the obligation, to take action against others in the courts, administrative agencies
or otherwise to prevent, terminate or seek damages on account of infringement, misappropriation,
illegal use or misuse of the Licensed Patent Rights or other Licensed Intellectual Property;
including such actions against others to prevent, terminate or seek damages on account of a
Symphony Collaboration Relevant Infringement. The costs and expenses of any such action shall be
borne by the Symphony Collaboration to the extent the action relates to a Symphony Collaboration
Relevant Infringement; provided, that the Symphony Collaboration’s written consent was obtained
prior to the initiation of such action, such consent not to be unreasonably withheld or delayed.
The Symphony Collaboration shall, at its expense, cooperate with and reasonably assist Licensor in
any such action if so requested by Licensor, and, upon Licensor’s request, execute, file and
deliver all documents and proof necessary for such purpose, including being named as a party to
such litigation if requested by Licensor or if


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





13









 







required by Law. The Symphony Collaboration shall have the right to participate and be
represented by its own counsel at its own expense in any such action, suit or proceeding with
respect to Licensed Patent Rights solely relating to Products for which Licensor has not exercised
the relevant Discontinuation Option; provided that the Symphony Collaboration shall not enter into
any settlement or compromise of such action, suit or proceeding that affects or concerns the
validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual
Property without the prior written consent of Licensor, which consent shall not be unreasonably
withheld or delayed. Except to the extent such settlement or compromise relates solely to
Licensor’s programs or products other than the Programs and the Products, Licensor shall not enter
into any settlement or compromise of such action, suit or proceeding that affects or concerns the
validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual
Property without the prior, written consent of the Symphony Collaboration, which consent shall not
be unreasonably withheld or delayed.




               (b) Subject to the limitations and restrictions set forth on Schedule 2.2, if, (1)
during the Term, the Symphony Collaboration requests Licensor to take action pursuant to
Section 4.6(a) with respect to a Symphony Collaboration Relevant Infringement that either
(i) solely involves the enforcement of a Program-Specific Patent or (ii) involves the enforcement
of other Licensed Intellectual Property relating exclusively to the Programs and there is not a
claim of an issued Program-Specific Patent, and (2) Licensor does not within [ * ] days of the
Symphony Collaboration’s written request take such action or provide the Symphony Collaboration
with a reasonable basis for not taking such action and subject to the Symphony Collaboration and
Licensor first engaging in good-faith discussions during such [ * ]-day period in an attempt to
balance the Parties’ respective interests, then the Symphony Collaboration shall have the option to
commence any such action under its own direction and control, and at the Symphony Collaboration’s
cost and expense; provided, that Licensor agrees that neither (x) the potential disturbance of an
actual or potential commercial relationship between Licensor and a third party nor (y) concerns
regarding potential risks to the Licensed Intellectual Property or other intellectual property
owned or controlled by Licensor is a reasonable basis for Licensor not taking such action.
Licensor shall, at the Symphony Collaboration’s expense, cooperate with and reasonably assist the
Symphony Collaboration in any such action if so requested by the Symphony Collaboration, and, upon
the Symphony Collaboration’s request, execute, file and deliver all documents and proof necessary
for such purpose, including being named as a party to such litigation if requested by the Symphony
Collaboration or if required by Law. Licensor shall have the right to participate and be
represented by its own counsel at its own expense in any such action, suit or proceeding with
respect to Licensed Patent Rights provided that , except to the extent such settlement or
compromise relates solely to Licensor’s programs or products other than the Programs and the
Products, Licensor shall not enter into any settlement or compromise of such action, suit or
proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed
Patent Rights or other Licensed Intellectual Property without the prior written consent of the
Symphony Collaboration, which consent shall not be unreasonably withheld or delayed. The Symphony


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





14









 







Collaboration shall not enter into any settlement or compromise of such action, suit or
proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed
Patent Rights or other Licensed Intellectual Property without the prior, written consent of
Licensor, which consent shall not be unreasonably withheld or delayed.




          4.7 Post-Term Enforcement.




               (a) Program-Specific Patents – First Right. Subject to the limitations and
restrictions set forth on Schedule 2.2, following the expiration or termination of the
Purchase Option without Licensor’s exercise of the Purchase Option, as between the Parties, and
solely with respect to Program-Specific Patents, the Symphony Collaboration shall have the first
right, but not the obligation, to take action against others, at the Symphony Collaboration’s cost
and expense, to prevent, terminate or seek damages on account of any Symphony Collaboration
Relevant Infringement. Licensor shall, at the Symphony Collaboration’s expense, cooperate and
reasonably assist the Symphony Collaboration in such action if so requested, and upon the Symphony
Collaboration’s request, execute, file and deliver all documents and proof necessary for such
purpose, including being named as a party to such litigation if requested by the Symphony
Collaboration or if required by Law. Licensor shall have the right to participate and be
represented in any such action, suit or proceeding by its own counsel at its own expense provided
that, except to the extent such settlement or compromise relates solely to Licensor’s programs or
products other than the Programs and the Products, Licensor shall not enter into any settlement or
compromise of such action, suit or proceeding that affects or concerns the validity,
enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property
without the prior written consent of the Symphony Collaboration, which consent shall not be
unreasonably withheld or delayed. The Symphony Collaboration shall not enter into any settlement
or compromise of such action, suit or proceeding that affects or concerns the validity,
enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property
without the prior written consent of Licensor, which consent shall not be unreasonably withheld or
delayed.



               (b) Program-Specific Patents – Reversion Right. Following the expiration or
termination of the Purchase Option without Licensor’s exercise of the Purchase Option, if the
Symphony Collaboration does not take action under Section 4.7(a) within [ * ] days of
Licensor’s written request that the Symphony Collaboration take such action, then Licensor shall
have the option to commence any such action under its own direction and control, and at Licensor’s
cost and expense. The Symphony Collaboration shall, at Licensor’s expense, cooperate and
reasonably assist Licensor in such action if so requested, and upon Licensor’s request, execute,
file and deliver all documents and proof necessary for such purpose, including being named as a
party to such litigation if requested by Licensor or if required by Law. The Symphony
Collaboration shall have the right to participate and be represented in any such action, suit or
proceeding by its own counsel at its own expense provided that the Symphony Collaboration shall not
enter into any settlement or compromise of such action, suit or


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.




15









 







proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed
Patent Rights or other Licensed Intellectual Property without the prior written consent of
Licensor, which consent shall not be unreasonably withheld or delayed. Except to the extent such
settlement or compromise relates solely to Licensor’s programs or products other than the Programs
and the Products, Licensor shall not enter into any settlement or compromise of such action, suit
or proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed
Patent Rights or other Licensed Intellectual Property without the prior written consent of the
Symphony Collaboration, which consent shall not be unreasonably withheld or delayed.




               (c) Licensed Intellectual Property. Except as set forth in Sections 4.7(a) and
4.7(b) above, following the expiration or termination of the Purchase Option without Licensor’s
exercise of the Purchase Option, as between the Parties, Licensor shall have the first right, but
not the obligation, to take action against others in the courts, administrative agencies or
otherwise, under Licensor’s direction and control and at Licensor’s cost and expense, to prevent or
terminate infringement, misappropriation, illegal use or misuse of any Licensed Intellectual
Property, including, but not limited to, a Symphony Collaboration Relevant Infringement. The
Symphony Collaboration shall, at Licensor’s expense, cooperate and reasonably assist Licensor in
such action if so requested, and upon Licensor’s request, execute, file and deliver all documents
and proof necessary for such purpose, including being named as a party to such litigation if
requested by Licensor or if required by Law. The Symphony Collaboration shall have the right to
participate and be represented in any such action, suit or proceeding by its own counsel at its own
expense, to the extent the action relates to a Symphony Collaboration Relevant Infringement;
provided that the Symphony Collaboration shall not enter into any settlement or compromise of such
action, suit or proceeding that affects or concerns the validity, enforceability, or ownership of
any Licensed Patent Rights or other Licensed Intellectual Property without the prior written
consent of Licensor, which consent shall not be unreasonably withheld or delayed. Except to the
extent such settlement or compromise relates solely to Licensor’s programs or products other than
the Programs and the Products, Licensor shall not enter into any settlement or compromise of such
action, suit or proceeding that affects or concerns the validity, enforceability, or ownership of
any Licensed Patent Rights or other Licensed Intellectual Property without the prior written
consent of the Symphony Collaboration, which consent shall not be unreasonably withheld or delayed.



               (d) Except as set forth in Sections 4.7(a) and 4.7(b) above and subject to the
limitations and restrictions set forth on Schedule 2.2, following the expiration or
termination of the Purchase Option without Licensor’s exercise of the Purchase Option, if Licensor
does not take action under Section 4.7(c) with respect to a Symphony Collaboration Relevant
Infringement, within [ * ] days of the Symphony Collaboration’s written request that Licensor take
such action, then the Symphony Collaboration shall have the option to commence any such action
under its own direction and control, and at the Symphony Collaboration’s cost and expense.
Licensor shall, at the Symphony Collaboration’s expense, cooperate and reasonably assist the
Symphony


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.






16









 







Collaboration in such action if so requested, and upon the Symphony Collaboration’s request,
execute, file and deliver all documents and proof necessary for such purpose, including being named
as a party to such litigation if requested by the Symphony Collaboration or if required by Law.
Licensor shall have the right to participate and be represented in any such action, suit or
proceeding by its own counsel at its own expense provided that, except to the extent such
settlement or compromise relates solely to Licensor’s programs or products other than the Programs
and the Products, Licensor shall not enter into any settlement or compromise of such action, suit
or proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed
Patent Rights or other Licensed Intellectual Property without the prior written consent of the
Symphony Collaboration, which consent shall not be unreasonably withheld or delayed. The Symphony
Collaboration shall not enter into any settlement or compromise of such action, suit or proceeding
that affects or concerns the validity, enforceability, or ownership of any Licensed Patent Rights
or other Licensed Intellectual Property without the prior written consent of Licensor, which
consent shall not be unreasonably withheld or delayed.




          4.8 Withdrawal of Enforcement. If either Party brings an action under this ARTICLE 4
with respect to a Symphony Collaboration Relevant Infringement and subsequently ceases to pursue or
withdraws from such action without resolution (which resolution may include the granting of a
license by Licensor to such third party that does not violate Section 2.2 or Section
2.6 of this Agreement), it shall promptly notify the other Party and the other Party may, to
the extent permitted by Law, substitute itself for the withdrawing Party under the terms of this
ARTICLE 4.




          4.9 Recoveries. All damages or other compensation of any kind recovered in such
action, suit, or proceeding brought under this ARTICLE 4 or from any related settlement or
compromise shall first be used to reimburse each Party for its expenses in connection with such
action, suit or proceeding, (in proportion to the expenses of each Party if recovery is
insufficient to cover all such expenses) and the remainder of such recovery, shall be allocated [ *
]% to[ * ].




ARTICLE 5

REPRESENTATIONS AND WARRANTIES




          5.1 Representations and Warranties of Licensor. Licensor hereby represents, warrants
and covenants to the Symphony Collaboration, that:




               (a) Subject to Section 3.2 and Schedule 2.2, Licensor is the exclusive owner
of all right, title, and interest in and to (i) all Licensed Patent Rights listed on Annex
C and not identified as jointly owned or licensed from a third party and (ii) the Regulatory
Files;



               (b) Licensor has sufficient rights to grant the licenses granted hereunder and the grant of
such licenses does not and will not conflict with any


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.






17









 







agreement to which Licensor is a party or otherwise governing the Licensed Intellectual
Property and Licensor further represents and warrants that, on an ongoing basis throughout the
Term, Licensor shall not enter into any agreement that will conflict with the rights and licenses
granted to the Symphony Collaboration hereunder;




               (c) To the Knowledge of Licensor, no third party is engaging in any activity that infringes or
misappropriates the Licensed Patent Rights or Licensed Know-How;



               (d) No Licensed Intellectual Property owned by Licensor and, to the Knowledge of Licensor, no
Licensed Intellectual Property licensed to Licensor has been adjudged invalid or unenforceable, in
whole or in part, and there is no pending or, to the Knowledge of Licensor, threatened action,
suit, proceeding or claim by others challenging the validity or enforceability of any Licensed
Intellectual Property, and Licensor is has no Knowledge of any facts which would support any such
claim;



               (e) To the Knowledge of Licensor, no actions or claims have been asserted, are pending or have
been threatened, against Licensor in writing alleging that the manufacture, use or sale of any
Product misappropriates or infringes the intellectual property rights of any third party;



               (f) Except as set forth on Annex B, Licensor and/or the Symphony Collaboration shall
not be liable or otherwise obligated to pay royalties, milestone payments or other consideration
pursuant to any agreement between Licensor and a third party existing on the Closing Date in
connection with the Symphony Collaboration’s exploitation of the Licensed Intellectual Property
(including Sublicensed Intellectual Property) in connection with the development, manufacture, use,
sale, or importation of Products hereunder;



               (g) To the Knowledge of Licensor, the manufacture, use or sale of any Product by the Symphony
Collaboration (or its sublicensees) in strict accordance with the licenses herein and other terms
of this Agreement will not misappropriate or infringe the intellectual property rights of any third
party, and Licensor has no Knowledge of any facts which would support any such claim;



               (h) The data and information relating to the Third Party License Agreements and the Programs
(including such data and information relating to pre-clinical and clinical studies) provided in
writing to the Symphony Collaboration or its Affiliates prior to the Closing Date has been accurate
in all material respects and, to the Knowledge of Licensor, Licensor has made no material
misrepresentation or material omission in connection with such data and information;



               (i) Licensor is not in breach or default under any of the Third Party License Agreements, and
to Licensor’s Knowledge there are no existing breaches or defaults by any other party to any of
the Third Party License Agreements; no event has


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.






18









 







occurred which (with notice, lapse of time or both) could reasonably be expected to constitute
a breach or default under any of the Third Party License Agreements by Licensor or to Licensor’s
Knowledge by any other party or give any other party the right to terminate, accelerate or modify
any Third Party License Agreement; Licensor will perform, in all material respects, its obligations
pursuant to the Third Party License Agreements, including those obligations related to Licensor’s
performance under the Operative Documents; and Licensor will not through any act or omission,
including any act or omission of Licensor pursuant to the Operative Documents, cause any breach or
default under, or otherwise cause the termination or amendment of, any Third Party License
Agreement; and




               (j) Except as set forth in Schedule 5.1, no “[ * ],” as defined in that certain
Research Collaboration and License Agreement between OXiGENE Europe AB and Bristol-Meyers Squibb
Company, dated as of December 15, 2999, relates to, or is exploitable in connection with, any
Licensed Intellectual Property, Regulatory Files, Products and/or Programs.



          5.2 Disclaimer and Acknowledgement. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 5,
THE LICENSED INTELLECTUAL PROPERTY, PRODUCTS, TANGIBLE MATERIALS AND REGULATORY FILES ARE PROVIDED
“AS IS” WITH NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, AND LICENSOR EXPRESSLY DISCLAIMS ALL
OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF
MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR NON-INFRINGEMENT. LICENSOR DOES NOT WARRANT
THE PERFORMANCE OF ANY PRODUCT, INCLUDING THEIR SAFETY, EFFECTIVENESS OR COMMERCIAL VIABILITY. ANY
THE SYMPHONY COLLABORATION ENHANCEMENT PROVIDED TO LICENSOR HEREUNDER ARE PROVIDED “AS IS” WITH NO
REPRESENTATIONS OR WARRANTIES OF ANY KIND AND SYMPHONY COLLABORATION EXPRESSLY DISCLAIMS ALL
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY,
FITNESS FOR PARTICULAR PURPOSE, OR NON-INFRINGEMENT.




ARTICLE 6

INDEMNIFICATION AND LIMITATION OF LIABILITY




          6.1 Indemnification.




               (a) To the greatest extent permitted by applicable law, the Licensor shall indemnify and hold
harmless the Symphony Collaboration, Holdings and RRD and each of their respective Affiliates,
officers, directors, employees, agents, members, managers, successors and assigns (each, a
“Symphony Indemnified Party”), and the Symphony Collaboration shall indemnify and hold
harmless the Licensor, and its Affiliates and each of their respective officers, directors,
employees, agents (other than


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.






19









 







the Company Subcontractors), members, managers, successors and assigns (each, a “Licensor
Indemnified Party”), from and against any and all claims, losses, costs, interest, awards,
judgments, fees (including reasonable fees for attorneys and other professionals), court costs,
liabilities, damages and expenses incurred by any Symphony Indemnified Party or Licensor
Indemnified Party (irrespective of whether any such Indemnified Party is a party to the action for
which indemnification hereunder is sought) (hereinafter, a “Loss”) to the extent resulting
from, arising out of, or relating to any and all third party suits, claims, actions, proceedings or
demands based upon:





               (i) in the case of the Licensor being the Indemnifying Party, (A) any breach of any
representation or warranty made by the Licensor herein or in any other Operative Document,
(B) any material misrepresentation or omission of facts in the public information of the
Licensor filed with the SEC, (C) any breach of any covenant, agreement or obligation of the
Licensor contained herein or in any other Operative Document, except to the extent such
covenant, agreement or obligation relates to the Licensor’s performance under the
Development Plan, (D) any gross negligence or willful misconduct of the Licensor (and not
that of any Company Subcontractors) in connection with the Licensor’s performance of its
obligations under this Agreement, (E) any action undertaken or performed by or on behalf of
the Licensor prior to, and including, the Closing Date that relates to the Programs or the
Products, (F) any regulatory matters relating to the Licensor, its businesses or its
assets, (G) any investigation or claim, including derivative claims, relating to the
Licensor, its businesses or its assets, or (H) in the event the Licensor exercises a
Discontinuation Option for a Program, any action undertaken and/or performed by or on
behalf of the Licensor after the Discontinuation Option Closing Date and relating to the
Product that was the subject of such Program (including the development, manufacture, use,
handling, storage, sale or other disposition of such Product); in each case, except (1)
with respect to Losses for which the Licensor is entitled to indemnification under this
ARTICLE 6 or (2) to the extent such Loss arises from the gross negligence or willful
misconduct of a Symphony Indemnified Party; and




               (ii) in the case of the Symphony Collaboration being the Indemnifying Party, (A) any
breach of any representation or warranty made by the Symphony Collaboration herein or in
any other Operative Document, (B) any breach of any covenant, agreement or obligation of
the Symphony Collaboration contained herein or in any other Operative Document, (C) any and
all activities undertaken or performed by or on behalf of the Parties under the Development
Plan during the Term, (D) any gross negligence or willful misconduct of the Symphony
Collaboration (and not that of its direct subcontractors) in connection with the Symphony
Collaboration’s performance of its obligations under this Agreement, or (E) the
development, manufacture, use, handling, storage, sale or other disposition of the Products
(including in the course of conducting the Programs) during the Term (except with respect
to the development, manufacture, use, handling, storage, sale or other disposition, after


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





20









 









the Licensor’s exercise of a Discontinuation Option, of Products covered under Section
15.2(a)(i)(H) of the Amended and Restated Research and Development Agreement); in each
case, except (1) with respect to Losses for which the Symphony Collaboration is entitled to
indemnification under this ARTICLE 6, or (2) to the extent such Loss arises from the gross
negligence or willful misconduct of a Licensor Indemnified Party.



          To the extent that the foregoing undertaking by the Licensor or the Symphony Collaboration may
be unenforceable for any reason, such Party shall make the maximum contribution to the payment and
satisfaction of any Loss that is permissible under applicable law.




          To the extent that the foregoing undertaking by the Licensor or the Symphony Collaboration may
be duplicated by any other undertaking by the Licensor or the Symphony Collaboration in any other
Operative Document, the Symphony Indemnified Parties or the Licensor Indemnified Parties, as the
case may be, shall be entitled to only one recovery under the Operative Documents for the relevant
Loss (and not entitled to any duplicative recovery for the same Loss).




          6.2 Notice of Claims. Any Indemnified Party that proposes to assert a right to be
indemnified under this ARTICLE 6 shall notify the Licensor or the Symphony Collaboration, as
applicable (the “Indemnifying Party”), promptly after receipt of notice of commencement of
any action, suit or proceeding against such Indemnified Party (an “Indemnified Proceeding”)
in respect of which a claim is to be made under this ARTICLE 6, or the incurrence or realization of
any Loss in respect of which a claim is to be made under this ARTICLE 6, of the commencement of
such Indemnified Proceeding or of such incurrence or realization, enclosing a copy of all relevant
documents, including all papers served and claims made, but the omission so to notify the
applicable Indemnifying Party promptly of any such Indemnified Proceeding or incurrence or
realization shall not relieve (x) such Indemnifying Party from any liability that it may have to
such Indemnified Party under this ARTICLE 6 or otherwise, except, as to such Indemnifying Party’s
liability under this ARTICLE 6, to the extent, but only to the extent, that such Indemnifying Party
shall have been prejudiced by such omission, or (y) any other indemnitor from liability that it may
have to any Indemnified Party under the Operative Documents.




          6.3 Defense of Proceedings. In case any Indemnified Proceeding shall be brought
against any Indemnified Party, it shall notify the applicable Indemnifying Party of the
commencement thereof as provided in Section 6.2, and such Indemnifying Party shall be
entitled to participate in, and provided such Indemnified Proceeding involves a claim solely for
money damages and does not seek an injunction or other equitable relief against the Indemnified
Party and is not a criminal or regulatory action, to assume the defense of, such Indemnified
Proceeding with counsel reasonably satisfactory to such Indemnified Party. After notice from such
Indemnifying Party to such Indemnified Party of such Indemnifying Party’s election so to assume the
defense thereof



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.





21











 




and the failure by such Indemnified Party to object to such counsel within [ * ] Business Days
following its receipt of such notice, such Indemnifying Party shall not be liable to such
Indemnified Party for legal or other expenses related to such Indemnified Proceedings incurred
after such notice of election to assume such defense except as provided below and except for the
reasonable costs of investigating, monitoring or cooperating in such defense subsequently incurred
by such Indemnified Party reasonably necessary in connection with the defense thereof. Such
Indemnified Party shall have the right to employ its counsel in any such Indemnified Proceeding,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Party unless:




          (a) the employment of counsel by such Indemnified Party at the expense of the applicable
Indemnifying Party has been authorized in writing by such Indemnifying Party;




          (b) such Indemnified Party shall have reasonably concluded in its good faith (which conclusion
shall be determinative unless a court determines that such conclusion was not reached reasonably
and in good faith) that there is or may be a conflict of interest between the applicable
Indemnifying Party and such Indemnified Party in the conduct of the defense of such Indemnified
Proceeding or that there are or may be one or more different or additional defenses, claims,
counterclaims, or causes of action available to such Indemnified Party (it being agreed that in any
case referred to in this clause (ii) such Indemnifying Party shall not have the right to direct the
defense of such Indemnified Proceeding on behalf of the Indemnified Party);




          (c) the applicable Indemnifying Party shall not have employed counsel reasonably acceptable to
the Indemnified Party to assume the defense of such Indemnified Proceeding within a reasonable time
after notice of the commencement thereof; provided, however, that (A) this clause (c) shall not be
deemed to constitute a waiver of any conflict of interest that may arise with respect to any such
counsel, and (B) an Indemnified Party may not invoke this clause (c) if such Indemnified Party
failed to timely object to such counsel pursuant to the first paragraph of this Section 6.3
(it being agreed that in any case referred to in this clause (c) such Indemnifying Party shall not
have the right to direct the defense of such Indemnified Proceeding on behalf of the Indemnified
Party); or




          (d) any counsel employed by the applicable Indemnifying Party shall fail to timely commence or
reasonably conduct the defense of such Indemnified Proceeding and such failure has prejudiced (or
is in immediate danger of prejudicing) the outcome of such Indemnified Proceeding (it being agreed
that in any case referred to in this clause (iv) such Indemnifying Party shall not have the right
to direct the defense of such Indemnified Proceeding on behalf of the Indemnified Party); in each
of which cases the fees and expenses of counsel for such Indemnified Party shall be at the expense
of such Indemnifying Party. Only one counsel shall be retained by all Indemnified Parties with
respect to any Indemnified Proceeding, unless counsel for any Indemnified Party reasonably
concludes in good faith (which conclusion shall be



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.




22









 








determinative unless a court determines that such conclusion was not reached reasonably and in
good faith) that there is or may be a conflict of interest between such Indemnified Party and one
or more other Indemnified Parties in the conduct of the defense of such Indemnified Proceeding or
that there are or may be one or more different or additional defenses, claims, counterclaims, or
causes or action available to such Indemnified Party.




          6.4 Settlement. Without the prior written consent of such Indemnified Party, such
Indemnifying Party shall not settle or compromise, or consent to the entry of any judgment in, any
pending or threatened Indemnified Proceeding, unless such settlement, compromise, consent or
related judgment (i) includes an unconditional release of such Indemnified Party from all liability
for Losses arising out of such claim, action, investigation, suit or other legal proceeding, (ii)
provides for the payment of money damages as the sole relief for the claimant (whether at law or in
equity), (iii) involves no admission of fact adverse to the Indemnified Party or finding or
admission of any violation of law or the rights of any Person by the Indemnified Party, and (iv) is
not in the nature of a criminal or regulatory action. No Indemnified Party shall settle or
compromise, or consent to the entry of any judgment in, any pending or threatened Indemnified
Proceeding (A) in respect of which any payment would result hereunder or under any other Operative
Document, (B) which includes an injunction that will adversely affect any Indemnifying Party, (C)
which involves an admission of fact adverse to the Indemnifying Party or a finding or admission of
any violation of law or the rights of any Person by the Indemnifying Party, (D) which is in the
nature of a criminal or regulatory action, without the prior written consent of the Indemnifying
Party, such consent not to be unreasonably conditioned, withheld or delayed, or (E) which admits
the invalidity, misuse or unenforceability of a Licensed Patent Right, without the prior written
consent of the Indemnifying Party, such consent not to be unreasonably conditioned, withheld or
delayed.




          6.5 Limitation of Liability. TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW,
NEITHER PARTY NOR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, MEMBERS, MANAGERS, EMPLOYEES,
INDEPENDENT CONTRACTORS OR AGENTS SHALL HAVE ANY LIABILITY OF ANY TYPE (INCLUDING, BUT NOT LIMITED
TO, CLAIMS IN CONTRACT, NEGLIGENCE AND TORT LIABILITY) FOR ANY SPECIAL, INCIDENTAL, INDIRECT,
PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING, BUT
NOT LIMITED TO, THE LOSS OF OPPORTUNITY, LOSS OF USE OR LOSS OF REVENUE OR PROFIT IN
CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR THE SERVICES PERFORMED HEREUNDER, EVEN IF SUCH
DAMAGES MAY HAVE BEEN FORESEEABLE. THE FOREGOING SHALL NOT LIMIT EITHER PARTY’S INDEMNIFICATION
OBLIGATIONS PURSUANT TO SECTION 6.1 .




          6.6 Insurance. The Parties shall maintain insurance as set forth in Section 6.7 of
the Amended and Restated Research and Development Agreement.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.






23









 








ARTICLE 7

TERM AND TERMINATION




          7.1 Term. This Agreement shall commence on the Closing Date and shall remain in force
until terminated as provided herein.




          7.2 Termination.




               (a) Either Party may terminate this Agreement at any time if the other Party is in material
default or breach of this Agreement that has resulted in, or would reasonably be expected to result
in, a material adverse effect on the Programs or the non-breaching Party’s rights under the
Operative Documents, and such material default or breach continues unremedied for a period of [ * ]
days after written notice thereof is delivered to the defaulting or breaching Party.



               (b) Licensor may terminate this Agreement at any time upon written notice to the Symphony
Collaboration if (i) Holdings breaches Section 2 of the Subscription Agreement or (ii) Holdings or
the Symphony Collaboration is in material default or breach of the Purchase Option Agreement that
has resulted in, or would reasonably be expected to result in, a material adverse effect on
Licensor’s rights under the Purchase Option Agreement and such default or breach is not cured
within [ * ] days after written notice of such default or breach under the Purchase Option
Agreement is delivered to the defaulting or breaching party.



               (c) Licensor may terminate the Symphony Collaboration’s sublicense to a specific element of
Sublicensed Intellectual Property if the Symphony Collaboration is in material default or breach of
a Sublicense Obligation relating to such Sublicensed Intellectual Property and such material
default or breach continues
unremedied for a period of [ * ] days (or such shorter cure period as may be stipulated in the
applicable Sublicense Obligation) after written notice thereof is delivered to the Symphony
Collaboration.



               (d) Upon any termination of this Agreement, all license rights granted herein (except for
those rights granted in or pursuant to Section 2.5) shall immediately terminate.



          7.3 Survival. The following Sections and Articles shall survive any expiration or
termination of this Agreement: Sections 4.1, 5.2 and 7.3, and
Articles 6 and 8.




          7.4 Bankruptcy. All rights and licenses granted under this Agreement are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the
“Bankruptcy Code”), licenses to “Intellectual Property” as defined in the
Bankruptcy Code. The Parties agree that each Party shall retain and may fully exercise all of its
rights and elections under the Bankruptcy Code.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.






24









 








ARTICLE 8

MISCELLANEOUS




          8.1 Notices. Any notice, request, demand, waiver, consent, approval or other
communication which is required or permitted to be given to any Party shall be in writing addressed
to the Party at its address set forth below and shall be deemed given (i) when delivered to the
Party personally, (ii) if sent to the Party by facsimile transmission (promptly followed by a
hard-copy delivered in accordance with this Section 8.1), when the transmitting Party
obtains written proof of transmission and receipt; provided, however, that notwithstanding the
foregoing, any communication sent by facsimile transmission after 5:00 PM (receiving Party’s time)
or not on a Business Day shall not be deemed received until the next Business Day, (iii) when
delivered by next Business Day delivery by a nationally recognized courier service, or (iv) if sent
by registered or certified mail, when received, provided postage and registration or certification
fees are prepaid and delivery is confirmed by a return receipt:




	 	 	 	 	 
	 

	 	Licensor:	 	 
	 

	 	 	 	OXiGENE, Inc.
	 

	 	 	 	230 Third Avenue
	 

	 	 	 	Waltham, MA 02451
	 

	 	 	 	Attn: Chief Executive Officer
	 

	 	 	 	Facsimile: (781) 547-6800
	 
	 	 	 	 
	 	 	The Symphony Collaboration:
	 
	 	 	 	 
	 

	 	 	 	Symphony ViDA, Inc.
	 

	 	 	 	7361 Calhoun Place, Suite 325
	 

	 	 	 	Rockville, MD 20855
	 

	 	 	 	Attn: Charles W. Finn, Ph.D.
	 

	 	 	 	Facsimile: (301) 762-6154
	 
	 	 	 	 
	 

	 	Holdings:	 	 
	 
	 	 	 	 
	 

	 	 	 	Symphony ViDA Holdings LLC
	 

	 	 	 	7361 Calhoun Place, Suite 325
	 

	 	 	 	Rockville, MD 20855
	 

	 	 	 	Attn: Robert L. Smith, Jr.
	 

	 	 	 	Facsimile: (301) 762-6154
	 
	 	 	 	 
	 

	 	with copies to:	 	 
	 
	 	 	 	 
	 

	 	 	 	Symphony Capital Partners, L.P.
	 

	 	 	 	875 Third Avenue, 18th Floor
	 

	 	 	 	New York, NY 10022
	 

	 	 	 	Attn: Mark Kessel
	 

	 	 	 	Facsimile: (212) 632-5401





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.





25









 








	 	 	 	 	 
	 

	 	and	 	 
	 

	 	 	 	Symphony Strategic Partners, LLC
	 

	 	 	 	875 Third Avenue, 18th Floor
	 

	 	 	 	New York, NY 10022
	 

	 	 	 	Attn: Mark Kessel
	 

	 	 	 	Facsimile: (212) 632-5401





or to such other address as such Party may from time to time specify by notice given in the manner
provided herein to each other Party entitled to receive notice hereunder.




          8.2 Entire Agreement. This Agreement (including any Annexes, Schedules, Exhibits or
other attachments hereto) and the agreements referred to herein (including the Operative Documents)
constitute the entire agreement between the Parties with respect to the subject matter hereof, and
no oral or written statement may be used to interpret or vary the meaning of the terms and
conditions hereof. This Agreement supersedes all prior and contemporaneous agreements,
correspondence, discussion and understandings, whether written or oral, between the Parties with
respect to the subject matter hereof, including the Original Agreement but excluding the Operative
Documents.




          8.3 Assignment. Neither Party may assign or otherwise transfer this Agreement without
the prior written consent of the other Party; provided, however, that (i) Licensor may assign this
Agreement or any of its rights and obligations hereunder without the consent of the Symphony
Collaboration (A) to an Affiliate or in connection with a merger or the sale of all or
substantially all of the assets of Licensor to which this Agreement relates, or (B) to the
Surviving Entity in the event Licensor undergoes a Change of Control in compliance with Article 14
of the Amended and Restated Research and Development Agreement, provided, however, the Licensed
Patent Rights and Licensed Know-How shall not be construed, as a result of such assignment, to
include any patent rights, know-how, trade secret, and other intellectual property that, prior to
such Change of Control, were owned or Controlled by the Person (other than Licensor) involved in
such Change of Control; and (ii) after the expiration or termination of the Purchase Option without
Licensor’s exercise of the Purchase Option, the Symphony Collaboration may assign or otherwise
transfer this Agreement to any Person without the prior, written consent of Licensor. Assignment
of this Agreement by either Party shall not relieve the assignor of its obligations hereunder.
This Agreement shall be binding upon and inure to the benefit of the Parties and their respective
successors and permitted assigns.




          8.4 Headings. The descriptive headings contained in this Agreement are for
convenience of reference only and shall not affect in any way the meaning or interpretation of the
Agreement.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.





26









 








          8.5 Independent Contractor. Each Party shall be acting as an independent contractor
in performing under this Agreement and shall not be considered or deemed to be an agent, employee,
joint venturer or partner of the other Party.




          8.6 Severability. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any rule Law or public policy, all other conditions and
provisions of this Agreement shall nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions contemplated hereby is not affected in any manner
materially adverse to any Party. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the Parties as closely as possible
in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the
extent possible.




          8.7 No Third-Party Beneficiaries. Except with respect to certain indemnification
obligations and liability limitations pursuant to this ARTICLE 6, nothing in this Agreement, either
express or implied, is intended to or shall confer upon any third party any legal or equitable
right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.




          8.8 Compliance with Laws. In performing under this Agreement, each Party shall comply
with all applicable Laws, rules and regulations, including without limitation the Federal Food,
Drug, and Cosmetic Act and regulations promulgated pursuant thereto and the United States Export
Administration Regulations.




          8.9 Amendment. The terms of this Agreement shall not be altered, modified, amended,
waived or supplemented in any manner whatsoever except by a written instrument signed by Licensor
and the Symphony Collaboration.




          8.10 Governing Law; Consent to Jurisdiction and Service of Process.




               (a) This Agreement shall be governed by, and construed in accordance with, the laws of the
State of New York; except to the extent that this Agreement pertains to the internal governance of
the Symphony Collaboration or Holdings, and to such extent this Agreement shall be governed and
construed in accordance with the laws of the State of Delaware.



               (b) Each of the Parties hereby irrevocably and unconditionally submits, for itself and its
property, to the nonexclusive jurisdiction of any New York State court or federal court of the
United States of America sitting in the County of New York in the State of New York, and any
appellate court from any jurisdiction thereof, in any action or proceeding arising out of or
relating to this Agreement, or for recognition or enforcement of any judgment, and each of the
Parties hereby irrevocably and unconditionally agrees that all claims in respect of any such action
or proceeding may be heard and determined in any such New York State court or, to the fullest
extent


Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.




27









 







permitted by Law, in such federal court. Each of the Parties agrees that a final judgment in
any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by
suit on the judgment or in any other manner provided by Law. Nothing in this Agreement shall
affect any right that any Party may otherwise have to bring any action or proceeding relating to
this Agreement.




               (c) Each of the Parties irrevocably and unconditionally waives, to the fullest extent it may
legally and effectively do so, any objection that it may now or hereafter have to the laying of
venue of any suit, action or proceeding arising out of or relating to this Agreement in any New
York State or federal court. Each of the Parties hereby irrevocably waives, to the fullest extent
permitted by Law, the defense of an inconvenient forum to the maintenance of such action or
proceeding in any such court.



          8.11 Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ALL RIGHT TO
TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR
OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT.




          8.12 Counterparts. This Agreement may be executed in one or more counterparts, and by
the respective Parties in separate counterparts, each of which when executed shall be deemed to be
an original but all of which taken together shall constitute one and the same Agreement.




          8.13 No Waiver. The failure of either Party to enforce at any time for any period the
provisions of or any rights deriving from this Agreement shall not be construed to be a waiver of
such provisions or rights or the right of such Party thereafter to enforce such provisions.




SIGNATURES FOLLOW ON NEXT PAGE



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.





28









 








          IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the
date first written above by their respective duly authorized officers.




	 	 	 	 	 	 	 
	 	 	SYMPHONY ViDA HOLDINGS LLC	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony Capital Partners, L.P., 

its Manager	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony Capital GP, L.P., 

its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony GP, LLC, 

its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Mark Kessel
 

Name: Mark Kessel
	 	 
	 

	 	 	 	Title: Managing Member	 	 
	 
	 	 	 	 	 	 
	 	 	SYMPHONY ViDA, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Mark Kessel	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Mark Kessel	 	 
	 

	 	 	 	Title: Chairman of the Board	 	 
	 
	 	 	 	 	 	 
	 	 	OXiGENE, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	John A. Kollins	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: John A. Kollins	 	 
	 

	 	 	 	Title: Chief Operating Officer	 	 






[Signature Page to Notvated and Restated Technology License Agreement]



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.















 








ANNEX A




CERTAIN DEFINITIONS




See attached.



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.





A-1









 








ANNEX B




CERTAIN ROYALTY AND MILESTONE PAYMENTS



Notwithstanding anything in this Agreement or this Annex B to the contrary, any royalty
payment, milestone or any other payment obligation to any third party licensor of Licensed
Intellectual Property shall be shared by the Parties in amounts and/or percentages to be agreed
upon by the Parties if such payment relates (but does not relate solely) to the manufacture, use,
sale or other commercialization of any Product by the Symphony Collaboration (including, without
limitation, by Licensor in the performance of the Amended and Restated Research and Development
Agreement).



1. ASU License Agreement



(a) A milestone payment of $[ * ] is payable as a license fee for each exercise, on behalf of or
for the benefit of the Symphony Collaboration, of the Option granted pursuant to Paragraph 2.1.2 of
the ASU License Agreement (as defined in Schedule 2.2 to this Agreement), plus ten payments
of $[ * ] each per compound for which the Option is exercised payable upon each June 1 and December
1 following the date of the notice of exercise of the Option for such compound.



(b) A royalty of [ * ]% shall be due on Net Sales (as defined in the ASU License Agreement)
within the United States, Canada or in any member country of the European Patent Organization of
Products covered by a valid claim in at least one pending or issued ASU Licensed Patent Right (as
defined in Annex C to this Agreement).



(c) A royalty of [ * ]% shall be due on Net Sales (as defined in the ASU License Agreement) in all
other countries of Products covered by a pending or issued ASU Licensed Patent Right.



(d) A minimum annual royalty of $[ * ] shall be due beginning in the year of first receipt of
marketing approval from the US Food and Drug Administration or any other analogous worldwide
regulatory agency for a Product covered by a valid claim in at least one pending or issued ASU
License Patent Right; provided, however, that for the year in which such approval is received, the
obligation to pay the minimum annual royalty shall be pro-rated for the number of full months
remaining in the calendar year following receipt of such approval.



2. Baylor License Agreement



(a) A royalty of [ * ]% shall be due on the Net Sales (as defined in the Baylor License Agreement,
which itself is defined in Schedule 2.2 to this Agreement) of all Products covered by a
valid claim in at least one pending or issued Baylor Licensed Patent Right (as defined in Annex
C to this Agreement) deriving from U.S. Patent No. 5,886,025 or International Patent
Application PCT/US98/04380, but no other Baylor Licensed Patent



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.





B-1









 







Right. A royalty of [ * ]% shall be due on the Net Sales (as defined in the Baylor License
Agreement) of all Products covered by a valid claim in at least one pending or issued Baylor
Licensed Patent Right other than those deriving from U.S. Patent No. 5,886,025 or International
Patent Application PCT/US98/04380.



(b) Licensor shall, at the sole discretion and direction of the Symphony Collaboration, on an
on-going basis, (i) refund to the Symphony Collaboration any royalties received from the Symphony
Collaboration that are not paid to Baylor University under the Baylor License Agreement, or (ii)
credit any royalties received from the Symphony Collaboration that are not paid to Baylor
University under the Baylor License Agreement toward future or other payments payable by the
Symphony Collaboration under the Baylor License Agreement.



(c) In the event that the Symphony Collaboration makes a payment to one or more third parties for
licensed to biological materials, patent rights, or know-how which the Symphony Collaboration
reasonably believes is necessary or proper to commercialize a Product covered by a valid claim in
at least one pending or issued Baylor Licensed Patent Right, any royalty payments due pursuant
paragraph 2(a) if this Annex B shall be reduced by the amount of payments made to said
third parties; provided, however, that the royalty shall not be reduced to less than [ * ] percent
([ * ]%) of the amount that would otherwise have been due in any period in the absence of such
payments to said third parties.



(d) In the event that any Development Product (as defined in Annex A to this Agreement) is
covered by a valid claim in at least one pending or issued Baylor Licensed Patent Right, commencing
in the first calendar year in which no research funding is provided to Baylor University pursuant
to Article 2 of the Baylor License Agreement, a minimum annual royalty of $[ * ] per year shall be
payable to Baylor University. All royalties actually paid to Baylor University for the calendar
year in which such Minimum Annual Royalty accrued shall be creditable against the minimum annual
royalty.



3. BMS License Agreement



(a) A royalty of [ * ]% shall be due on world-wide Net Sales (as defined in the BMS License
Agreement, which itself is defined in Schedule 2.2 to this Agreement) of all Products
covered by a valid claim of at least one pending or issued BMS Licensed Patent Right (as defined in
Annex C to this Agreement).



4. Angiogene License Agreement



(a) A royalty of [ * ]% shall be due on Net Sales (as defined in the Angiogene License Agreement,
which itself is defined in Schedule 2.2 to this Agreement) of all Products covered by a
valid claim of at least one pending or issued Angiogene License Patent Right (as defined in
Annex C to this Agreement). Licensor shall, at the sole discretion and direction of the
Symphony Collaboration, on an on-going basis, (i) refund to the Symphony Collaboration any
royalties received from the Symphony Collaboration



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.




B-2









 







that are not paid to Angiogene Pharmaceuticals, Ltd. under the Angiogene License Agreement, or (ii)
credit any royalties received from the Symphony Collaboration that are not paid to Angiogene
Pharmaceuticals, Ltd. under the Angiogene License Agreement toward future or other payments payable
by the Symphony Collaboration under the Angiogene License Agreement.



(b) A non-refundable annual minimum royalty of [ * ] dollars ($[ * ]) is payable (i) within [ * ]
days of the First Commercial Sale (as defined in the Angiogene License Agreement) of a Product
covered by a valid claim of an Angiogene Licensed Patent Right or (ii) on August 22, 2009,
whichever shall occur first. A similar payment is due one each subsequent anniversary of such
date. Such amount shall be fully creditable against royalties due for the annual period following
payment. If any delay in achieving First Commercial Sale (as defined in the Angiogene License
Agreement) was due to a Force Majeure (as defined in the Angiogene License Agreement), the August
22, 2009 date shall be extended for the time that was lost due to the Force Majeure.



(c) In the event that, in order to make, use or sell any Product covered by a valid claims of at
least one pending or issued Angiogene License Patent Right, the Symphony Collaboration is also
obligated to make royalty payments to one or more third parties under license agreements to
intellectual property rights reasonably necessary for such manufacture, use or sale, then the
Symphony Collaboration shall have the right to reduce the royalties otherwise due pursuant
paragraph 4(a) if this Annex B for such Product by [ * ] percent ([ * ]%) of the amount
actually paid to any such third party in the relevant royalty period. Notwithstanding the
foregoing, such reductions shall In no event reduce the royalty for any such Product to less than [
* ] percent ([ * ]%) of the rates otherwise specified.



5. Definitions of Licensed Patent Rights



(a) “ASU Licensed Patent Rights” shall mean all Licensed Patent Rights licensed to Licensor
or its Affiliates pursuant to the ASU License Agreement (as defined in Schedule 2.2 to this
Agreement), including the following patents and patent applications and any corresponding
extensions or foreign applications or patents:




	 	 	 	 	 	 	 	 	 
	 	 	 	 	ASU Licensed Patent Rights
	 
	 	Application No.
	 	Filing Date	 	 	 	 
	 
	 	Publication No.
	 	Pub. Date	 	 	 	 
	Country
	 	Patent No.
	 	Issue Date
	 	Owner
	 	Title
	 
	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]





(b) “Baylor Licensed Patent Rights” shall mean all Licensed Patent Rights
licensed to Licensor or its Affiliates pursuant to the Baylor License Agreement (as
defined in Schedule 2.2 to this Agreement), including all the following patent and
patent applications and any patents issuing from said applications, including any foreign
filings, divisions, continuations, continuations-in-part, reexaminations, extensions, or
reissues:



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.





B-3









 








	 	 	 	 	 	 	 	 	 
	 	 	 	 	Baylor Licensed Patent Rights
	 
	 	Application No.
	 	Filing Date	 	 	 	 
	 
	 	Publication No.
	 	Pub. Date	 	 	 	 
	Country
	 	Patent No.
	 	Issue Date
	 	Owner
	 	Title
	 
	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]





(c) “BMS Licensed Patent Rights” shall mean all Licensed Patent Rights licensed to Licensor
or its Affiliates pursuant to the BMS License Agreement (as defined in Schedule 2.2 to this
Agreement), including the following patents and patent applications as well as any and all
substitutions, extensions, renewals, continuations, continuations-in-part, divisions,
patents-of-addition and/or reissues thereof and all foreign and/or PCT counterparts thereto:




	 	 	 	 	 	 	 	 	 
	 	 	 	 	BMS Licensed Patent Rights
	 
	 	Application No.
	 	Filing Date	 	 	 	 
	 
	 	Publication No.
	 	Pub. Date	 	 	 	 
	Country
	 	Patent No.
	 	Issue Date
	 	Owner
	 	Title
	 
	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]





(d) “Angiogene Licensed Patent Rights” shall mean all Licensed Patent Rights licensed to
Licensor or its Affiliates pursuant to the Angiogene License Agreement (as
defined in Schedule 2.2 to this Agreement), including the following patents and patent
applications as well as any and all substitutions, extensions, renewals, continuations,
continuations-in-part, divisions, patents-of-addition and/or reissues thereof and all foreign
and/or PCT counterparts thereto:




	 	 	 	 	 	 	 	 	 
	 	 	 	 	Angiogene Licensed Patent Rights
	 
	 	Application No.
	 	Filing Date	 	 	 	 
	 
	 	Publication No.
	 	Pub. Date	 	 	 	 
	Country
	 	Patent No.
	 	Issue Date
	 	Owner
	 	Title
	 
	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.





B-4









 








ANNEX C




CERTAIN LICENSED PATENTS RIGHTS





	1.	 	The ASU Licensed Patent Rights, including the patents and patent applications listed in
Paragraph 5(a) of Annex B to this Agreement;






	2.	 	The Baylor Licensed Patent Rights, including the patents and patent applications listed in
Paragraph 5(b) of Annex B to this Agreement;






	3.	 	The BMS Licensed Patent Rights, including the patents and patent applications listed in
Paragraph 5(c) of Annex B to this Agreement;






	4.	 	The Angiogene Licensed Patent Rights, including the patents and patent applications listed in
Paragraph 5(d) of Annex B to this Agreement; and
	 
	5.	 	The following Licensed Patent Rights:





	 	 	 	 	 	 	 	 	 
	 
	 	Application No.
	 	Filing Date	 	 	 	 
	 
	 	Publication No.
	 	Pub. Date	 	 	 	 
	Country
	 	Patent No.
	 	Issue Date
	 	Owner
	 	Title
	 
	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.





C-1









 








SCHEDULE 2.2




CERTAIN RESTRICTIONS RELATING TO LICENSED INTELLECTUAL

PROPERTY LICENSED TO LICENSOR BY A THIRD PARTY




1. Arizona State University:



(a) The Symphony Collaboration acknowledges that certain Sublicensed Intellectual Property is
licensed to Licensor or its Affiliates by the Arizona Board of Regents, acting on behalf of and for
Arizona State University (“ASU”) and will be sublicensed to the Symphony Collaboration
hereunder and that such sublicense is subject to the restrictions and obligations set forth in the
License Agreement No. 206-01.LIC dated 2 August 1999, as amended by the Amendment and Confirmation
of License Agreement No. 206-01.LIC dated 10 June 2002, and the Second Amendment of License
Agreement No. 206-01.LIC dated 15 September 2004, and clarified by the Clarification of
Intellectual Property Rights dated 11 August 2003 (collectively, the “ASU License
Agreement”).



(b) In particular, but not the exclusion of its other obligations under the ASU License, the
Symphony Collaboration acknowledges (i) its obligation, if it shall become aware of any
infringement or threatened infringement of any of ASU Licensed Patent Rights (as defined in
Annex C to this Agreement), to give immediate notice of infringement or threatened
infringement to ASU; (ii) its obligation to give reasonable assistance to ASU in enforcing the ASU
Licensed Patent Rights, and (iii) its right to join in any infringement or enforcement action at
its own expense to recover damages for injury to the Symphony Collaboration resulting from such
infringement.



(c) Upon receipt of notice from ASU that ASU is not able or willing to take action against an
infringer as set forth above, the Licensor and/or the Symphony Collaboration, after giving ASU
written notice of its intention to do so, may at its or their own expense take action. The
royalties specified in Article 5 of the ASU License Agreement shall be paid to ASU on that portion
of any recovery remaining after reimbursement of all of the Licensor’s and/or Symphony
Collaboration’s expenses hereunder.



2. Baylor University: The Symphony Collaboration acknowledges that certain Sublicensed
Intellectual Property is licensed to Licensor or its Affiliates by Baylor University and will be
sublicensed to the Symphony Collaboration hereunder and that such sublicense is subject to the
restrictions and obligations set forth in the Research and License Agreement between OXiGENE, Inc.
and Baylor University dated 1 June 1999, as amended by the Agreement to Amend Research and License
Agreement dated 23 April 2002, the undated Addendum attached as Exhibit 10.30 to Licensor’s 10-K/A
dated 12 August 2003, and the Addendum dated 15 February 2007 (collectively, the “Baylor
License Agreement”).



3. Bristol-Myers Squibb Company: The Symphony Collaboration acknowledges that certain Sublicensed
Intellectual Property is licensed to Licensor or its Affiliates by



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.





1









 







Bristol-Myers Squibb Company and will be sublicensed to the Symphony Collaboration hereunder and
that such sublicense is subject to the restrictions and obligations set forth in the Termination
Agreement between OXiGENE Europe AB and Bristol-Myers Squibb Company dated 15 February 2002, as
amended by the Amendment and Confirmation of Termination Agreement dated 9 September 2008
(collectively, the “BMS License Agreement”).



4. Angiogene Pharmaceuticals Ltd.: The Symphony Collaboration acknowledges that certain
Sublicensed Intellectual Property is licensed to Licensor or its Affiliates by Angiogene
Pharmaceuticals Ltd. and will be sublicensed to the Symphony Collaboration hereunder and
that such sublicense is subject to the restrictions and obligations set forth in Exclusive
License Agreement between OXiGENE, Inc. and Angiogene Pharmaceuticals, Ltd. dated 22
August 2005, as amended by the Amendment No. 1 dated 1 March 2006 (collectively, the
“Angiogene License Agreement”).



Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.




2









 








SCHEDULE 5.1




[ * ] THAT RELATES TO OR IS EXPLOITABLE IN CONNECTION WITH 

LICENSED INTELLECTUAL PROPERTY,
REGULATOR FILES, PRODUCTS

AND/PROGRAMS




	 	 	 	 	 	 	 	 	 
	 
	 	Application No.
	 	Filing Date	 	 	 	 
	 
	 	Publication No.
	 	Pub. Date	 	 	 	 
	Country
	 	Patent No.
	 	Issue Date
	 	Owner
	 	Title
	 
	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]
	 	[ * ]





Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2
of the Securities Exchange Act of 1934, as amended.